Namenda, Ebixa(memantine)
Axura, Ebixa, Marixino, Maruxa, Memantine, Namenda, Namzaric, Nemdatine (memantine) is a small molecule pharmaceutical. Memantine was first approved as Ebixa on 2002-05-15. It is used to treat alzheimer disease in the USA. It has been approved in Europe to treat alzheimer disease. It is known to target glutamate receptor ionotropic, NMDA 2C.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
Memantine, Namenda (discontinued: Memantine, Namenda)
CombinationsMemantine donepezil, Namzaric (discontinued: Memantine donepezil)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| generic drug | unapproved drug other | 2019-05-07 |
| ibuprofen | ANDA | 2014-12-05 |
| memantine | ANDA | 2024-09-26 |
| memantine and donepezil hydrochlorides extended-release | ANDA | 2020-12-29 |
| memantine hcl | ANDA | 2024-02-29 |
| memantine hydrochloride | ANDA | 2024-11-07 |
| memantine hydrochloride memantine hydrochloride | ANDA | 2021-12-22 |
| namenda | New Drug Application | 2019-11-30 |
| namenda namenda xr | New Drug Application | 2017-12-28 |
| namzaric | New Drug Application | 2024-05-13 |
Show 1 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| alzheimer disease | EFO_0000249 | D000544 | F03 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Donepezil Hydrochloride / Memantine Hydrochloride, Namzaric, Abbvie | |||
| 8058291 | 2029-12-05 | U-1641 | |
| 8039009 | 2029-03-24 | U-539, U-1641 | |
| 8168209 | 2025-11-22 | DP | |
| 8173708 | 2025-11-22 | U-1641 | |
| 8283379 | 2025-11-22 | U-1641 | |
| 8293794 | 2025-11-22 | DP | |
| 8329752 | 2025-11-22 | DP | |
| 8338485 | 2025-11-22 | DP | |
| 8338486 | 2025-11-22 | U-1641 | |
| 8362085 | 2025-11-22 | U-1641 | |
| 8580858 | 2025-11-22 | U-1641 | |
| 8598233 | 2025-11-22 | DP | |
HCPCS
No data
Clinical
Clinical Trials
253 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | 3 | 5 | 1 | 9 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | 2 | — | 3 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | 2 | — | 2 |
| Aphasia | D001037 | HP_0002381 | R47.01 | — | — | — | 2 | — | 2 |
| Aggression | D000374 | EFO_0003015 | — | — | — | — | 1 | 1 | 2 |
| Atrophy | D001284 | — | — | — | — | — | 1 | — | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | 1 | — | 1 |
| Lewy body disease | D020961 | EFO_0006792 | G31.83 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sclerosis | D012598 | — | — | — | 2 | 2 | — | — | 3 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | 1 | — | — | 2 |
| Amyotrophic lateral sclerosis | D000690 | HP_0007354 | G12.21 | — | 1 | 1 | — | — | 1 |
| Motor neuron disease | D016472 | EFO_0003782 | G12.2 | — | 1 | 1 | — | — | 1 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | — | 1 | — | — | 1 |
| Cognition disorders | D003072 | — | — | — | — | 1 | — | — | 1 |
| Frontotemporal dementia | D057180 | HP_0002145 | G31.0 | — | — | 1 | — | — | 1 |
| Primary progressive aphasia | D018888 | EFO_0009053 | G31.01 | — | — | 1 | — | — | 1 |
| Pick disease of the brain | D020774 | EFO_0003096 | G31.01 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psychomotor agitation | D011595 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Memantine |
| INN | memantine |
| Description | Memantine is a primary aliphatic amine that is the 3,5-dimethyl derivative of 1-aminoadamantane. A low to moderate affinity uncompetitive (open-channel); NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. It has a role as a dopaminergic agent, an antiparkinson drug, a NMDA receptor antagonist, a neuroprotective agent and an antidepressant. It is a member of adamantanes and a primary aliphatic amine. It is a conjugate base of a memantinium(1+). It derives from a hydride of an adamantane. |
| Classification | Small molecule |
| Drug class | antivirals/antiparkinsonians (adamantane derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC12CC3CC(C)(C1)CC(N)(C3)C2 |
Identifiers
| PDB | — |
| CAS-ID | 19982-08-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL807 |
| ChEBI ID | 64312 |
| PubChem CID | 4054 |
| DrugBank | DB01043 |
| UNII ID | W8O17SJF3T (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
GRIN2C
GRIN2C
Organism
Homo sapiens
Gene name
GRIN2C
Gene synonyms
NMDAR2C
NCBI Gene ID
Protein name
glutamate receptor ionotropic, NMDA 2C
Protein synonyms
GluN2C(alt_5'UTR_77nt), GluN2C(alt_5'UTR_87nt), GluN2C(del_e2), GluN2C-b alternative isoform, Glutamate [NMDA] receptor subunit epsilon-3, glutamate receptor, ionotropic, N-methyl D-aspartate 2C, N-methyl D-aspartate receptor subtype 2C, N-methyl-D-aspartate receptor subunit 2C, NMDAR2C, NR2C, putative NMDtranscript(altAcc_e11), putative NMDtranscript(altDon_e4), putative NMDtranscript(del_e4)
Uniprot ID
Mouse ortholog
Grin2c (14813)
glutamate receptor ionotropic, NMDA 2C (Q01098)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Namenda – Allergan
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Namenda – Warner Chilcott
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Namzaric – Allergan
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Namzaric – Warner Chilcott
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Memantine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 19,954 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ibuprofen
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
13,191 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use